Early Promise for a New Parkinson’s Cell Therapy

Early results from a clinical trial testing ANPD001, an investigational cell therapy for Parkinson’s disease, are showing encouraging signs. The first three people treated experienced fewer motor symptoms and improvements in daily functioning after six months, with no serious side effects reported. These findings come from the Phase 1/2a ASPIRO study (NCT06344026), which is assessing the safety and potential benefits of ANPD001 in adults with moderate to advanced Parkinson’s disease. What is ANPD001? ANPD001 is designed to replace the specific brain cells that are lost in Parkinson’s—dopaminergic neurons, which help control movement. This therapy uses a person’s own skin cells, which are reprogrammed into stem cells in the lab and then turned into dopamine-producing neuron precursors. Once ready, these cells are surgically injected into a brain region called the putamen. The hope is that they will mature into healthy, functioning neurons, potentially helping to restore dopamine levels and improve motor control over time. Trial Participants and Procedures The ASPIRO study includes participants aged 50 to 70 who still respond to levodopa (a common Parkinson’s medication) but continue to experience motor challenges. Patients are monitored for one year after treatment and followed for up to 15 years to evaluate long-term safety and effects. So far, all participants have tolerated the procedure well. The first three received a lower dose of 5 million dopamine-producing cell precursors and were able to return home within 48 hours. Common side effects included temporary pain at the surgical site and mild tongue swelling from the position used during surgery. Improved Movement and Daily Life At the six-month mark: Patients had a 45% improvement in motor symptoms when off their regular medication, based on a clinical rating scale. They also showed a 71% improvement in their ability to perform daily activities like eating, dressing, and walking. On average, they gained 1.5 more hours per day of good "on" time—periods when symptoms are well-managed without unwanted side effects. They experienced two fewer hours per day of "off" time—when symptoms return despite medication. Importantly, there were no reports of bleeding or therapy-related involuntary movements (known as graft-induced dyskinesia). A Therapy with Fast-Track Status The U.S. Food and Drug Administration (FDA) has granted ANPD001 fast track designation, which could help speed up its development and review process. This status provides additional support from the FDA and allows the therapy to be considered for priority and accelerated approval in the future. A Step Forward While these results are early and based on a small number of participants, they offer hope for a therapy that could one day improve quality of life for people living with Parkinson’s. Researchers will continue to monitor participants closely and expand the study to learn more about how effective and safe ANPD001 might be over time.